Skip to navigation Skip to content

Cystic fibrosis (CF) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051113

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised ivacaftor, lumacaftor+ivacaftor, tezacaftor+ivacaftor and elexacaftor+tezacaftor+ivacaftor for patients with cystic fibrosis (CF).

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Cystic fibrosis (CF) quick reference

Table 1

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial

PB120 form

PB243 form

PB286 form

Written

Electronic

S100:

ivacaftor

lumacaftor+ivacaftor or tezacaftor+ivacaftor

elexacaftor+tezacaftor+ivacaftor

No

OPA

Must be treated by, or in consultation with:

  • a specialist respiratory physician

Yes - delayed assessment

Continuing

PB126 form

PB244 form

PB287 form

Written

Electronic

S100:

ivacaftor

lumacaftor+ivacaftor or tezacaftor+ivacaftor

elexacaftor+tezacaftor+ivacaftor

No

OPA

Must be treated by, or in consultation with:

  • a specialist respiratory physician

Yes - delayed assessment

Delayed assessment

Table 2: this table lists the details of what to check for the delayed assessment and common acronyms.

Delayed assessment due to concomitant CYP3A4 inhibitors, CYP3A4 inducers and IV antibiotics.

Service Officers to assess that free text is:

Examples

Outcome

Relevant to the question
  • Drug name(s)

Approve

Random text
  • Happy Birthday
  • Patient did not want to take
  • Ikasditbn

Reject

Non-descriptive
  • N/A or Not applicable

Approve

Common acronyms

  • LFT - Liver function tests
  • GI toxicity - Gastrointestinal
  • N+V - Nausea and vomiting

Escalate to a Pharmaceutical Adviser (PA) by phone if unsure of the acronym used.